CoChat

Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes

Sinclair, Elaine M, Drucker, Daniel J · 2005 · Current Opinion in Endocrinology & Diabetes
Cited by 39

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Purpose of review To summarize data that support energy deficit as a signal for inducing improvements in insulin sensitivity following exercise. Recent findings Insulin sensitivity improves prior to weight loss in diet change protocols and following gastric bypass surgery. Initial changes in insulin sensitivity with weight loss reverse when active weight loss ceases even if total weight loss from baseline persists. Rapid weight loss by liposuction without changes in energy balance does not change insulin sensitivity. Long-term exercise studies (12-14 weeks) on obese men and women demonstrate little improvement in insulin sensitivity when subjects increase caloric intake sufficiently to offset increased energy expenditure and not lose weight. Short-term exercise studies, which control for the confounding impact of chronic training and loss of body fat, suggest that the beneficial effect of exercise on insulin action is reversed when patients consume sufficient calories to offset their physical activity. Very recent data hint that the composition of the refed calories may be a strong determinant of the response. Summary Energy deficit needs to be present to derive the maximal benefits of exercise on insulin sensitivity. From a public health perspective, exercise programs that do not include decreased caloric intake may have minimal impact on rates of insulin resistance and its health consequences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.med.0000155379.11926.e2

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 39

Metadata

Authors
Sinclair, E. M., & Drucker, D. J.
Venue
Current Opinion in Endocrinology & Diabetes
Published
2005-04
Volume
12
Issue
2
Pages
146-151
ISSN
1068-3097 (ISSN-L)
OpenAlex
W2123207909
Cited by
39
References
19
FWCI
2.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1097/01.med.0000155379.11926.e2
The paper
Sinclair, E. M., & Drucker, D. J. (2005). Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Current Opinion in Endocrinology & Diabetes. https://doi.org/10.1097/01.med.0000155379.11926.e2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.